Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 9/20 | 0.47 |
| ▸ | INSR | P06213 | 8/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 9/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15156326 | 1.00 | ALK (0.47) | ALKINSRAURKBMAP3K7IRAK4 | |
| SCHEMBL16243440 | 0.90 | ALK (0.46) | ALKINSRAURKBIRAK4AURKA | |
| SCHEMBL17416610 | 0.90 | ALK (0.46) | ALKINSRAURKBIRAK4AURKA | |
| SCHEMBL17416520 | 0.88 | ALK (0.37) | ALKINSRAURKBAURKA | |
| SCHEMBL16243514 | 0.84 | ALK (0.60) | ALKINSRAURKB | |
| SCHEMBL17416618 | 0.84 | ALK (0.51) | ALKINSRAURKBMAP3K7IRAK4 | |
| SCHEMBL15172558 | 0.84 | ALK (0.60) | ALKINSRAURKB | |
| SCHEMBL16243423 | 0.84 | ALK (0.51) | ALKINSRAURKBMAP3K7IRAK4 | |
| SCHEMBL16243206 | 0.84 | ALK (0.48) | ALKINSRAURKBMAP3K7IRAK4 | |
| SCHEMBL17416609 | 0.81 | MEN1 (0.43) | ALKINSRAURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | claimed |
| EP-2809671-B1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON INC (US) | 2016-01-13 | — | — | EP | claimed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | claimed |
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2809671-B1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | JAK1, ALK, JAK2 | ALK 2/4885INSR 752/4885AURKB 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.